Replies to post #160790 on Biotech Values

[oc631]

RE:ACHN




This caught my eye in the PR

"Furthermore, we remain focused on evaluating additional assets with complementary mechanisms of action that could potentially expand our treatment regimens to treat subsets of patient populations not adequately addressed by current regimens."

This may suggest ACHN is considering licensing or entering an option license agreement for a nucleotide analog.